Halo Pharmaceutical: Cambrex Completes Acquisition of Halo Pharma

Cambrex, a manufacturer of small-molecule innovator and generic APIs, announced on Sept. 12, 2018 that it has acquired Halo Pharma, a dosage form contract development and manufacturing organization (CDMO) located in Whippany, NJ and Mirabel, Qu bec, Canada, for approximately $425 million.